

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 May 2022 (19.05.2022)



(10) International Publication Number
WO 2022/103705 A1

- (51) **International Patent Classification:**
C07K 16/40 (2006.01) *G01N 33/574* (2006.01)
A61P 35/00 (2006.01)
- (21) **International Application Number:**
PCT/US2021/058491
- (22) **International Filing Date:**
08 November 2021 (08.11.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/112,616 11 November 2020 (11.11.2020) US
- (71) **Applicant:** **VERSAPEUTICS INC.** [US/US]; 10210 Campus Point Dr, Suite 150, San Diego, CA 92121 (US).
- (72) **Inventors:** **HAUSER, David N.**; 10210 Campus Point Dr, Suite 150, San Diego, CA 92121 (US). **KAMPERT, Taylor L.**; 10210 Campus Point Dr, Suite 150, San Diego, CA 92121 (US). **SUN, Miao**; 10210 Campus Point Dr, Suite 150, San Diego, CA 92121 (US).
- (74) **Agent:** **CHEN, Peng** et al.; Rimon, P.C., 420 West Main Street, Suite 101b, Boise, ID 83702 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(54) **Title:** ANTIBODY VARIANTS AGAINST WNT RECEPTOR RYK

Figure 1: Ab5.5 VL domain with Chothia CDR definitions and numbering



(57) **Abstract:** The present disclosure relates to isolated anti-Ryk antibodies or antibody derivatives. In some aspects, the present disclosure relates to the use of the isolated anti-Ryk antibodies or antibody derivatives

WO 2022/103705 A1